Pulmokine, Inc.

UEI
CJAVXCPZUUM9
CAGE
4XMX0
Primary NAICS
541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
SAM.gov registration
Expired

Company facts

Self-certified in SAM.gov
  • For Profit Organization
Entity structure
Corporate Entity (Not Tax Exempt)
SAM.gov registration date
Website
pulmokine.net
Founded
2007
Employees
1-10
Estimated annual revenue
$1M-$10M
Industry
  1. Health Care
  2. Health Care Equipment & Services
  3. Health Care Providers & Services
SIC code
38 Instruments & Related Products
Profiles

Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .

Contract awards

Award Agency Obligated Awarded
Vascular interventions/innovations and therapeutic advances (vita): IND enabling studies for a novel inhaled pdgf… HHSN268201400013C National Heart Lung and Blood Institute (NIH) $1,549,477
An inhaled dry powder formulation for multi-drug resistant tuberculosis HHSN272201300015C NIAID DEA OA Acquisitions (NIH) $224,960

Grant awards

Award Agency Obligated Awarded
A phosphopeptide multiplex PRM mass spectroscopic biomarker assay for PAH R43HL135910 National Heart Lung and Blood Institute (NIH) $482,321
A novel inhaled c-kit/pdgfr inhibitor for the treatment of asthma R43HL132709 National Heart Lung and Blood Institute (NIH) $337,324
An inhaled pdgf receptor inhibitor for the treatment of pulmonary arterial hyper R44HL102946 National Heart Lung and Blood Institute (NIH) $5,271,635
Phosphopeptide mapping of plexiform lesions in pulmonary arterial hypertension R03HL110821 National Institutes of Health $145,000
A pdgfr inhibitor for the treatment of pulmonary arterial hypertension R43HL102946 National Institutes of Health $351,008

Latest 5 listed here. See the rest on GovTribe.

Quick answers

Is Pulmokine, Inc. registered in SAM.gov?

Pulmokine, Inc.'s SAM.gov registration expired on October 5, 2020.

What is Pulmokine, Inc.'s most recent federal award?

Pulmokine, Inc.'s most recent federal grant award is A phosphopeptide multiplex PRM mass spectroscopic biomarker assay for PAH (R43HL135910), from National Heart Lung and Blood Institute (NIH), on April 1, 2017.

On GovTribe

See Pulmokine, Inc.'s full federal record

  • Federal contract awards
  • Federal grant awards
  • Funding analysis by agency, NAICS and set-aside
  • Similar vendors
Try for free Login